Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey

Basit Öğe Kaydı
dc.contributor.authorKaracaer, Zehra
dc.contributor.authorCakir, Banu
dc.contributor.authorErdem, Hakan
dc.contributor.authorUgurlu, Kenan
dc.contributor.authorDurmus, Gul
dc.contributor.authorInce, Nevin Koc
dc.contributor.authorOzturk, Cinar
dc.date.accessioned2024-04-24T17:14:54Z
dc.date.available2024-04-24T17:14:54Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors. Methods: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant. Results: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided. Conclusions: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.en_US
dc.identifier.doi10.1186/s12955-016-0557-9
dc.identifier.issn1477-7525
dc.identifier.pmid27809934
dc.identifier.scopus2-s2.0-85009282225
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1186/s12955-016-0557-9
dc.identifier.urihttps://hdl.handle.net/11468/18253
dc.identifier.volume14en_US
dc.identifier.wosWOS:000386954300001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherBmcen_US
dc.relation.ispartofHealth and Quality of Life Outcomes
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic Hepatitis B Infectionen_US
dc.subjectQuality Of Lifeen_US
dc.subjectThe Hepatitis B Quality Of Life Instrumenten_US
dc.subjectTurkeyen_US
dc.titleQuality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkeyen_US
dc.titleQuality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu